SIN-1 chloride
(Synonyms: 5-氨基-3-(4-吗啉基)-1,2,3-恶二唑盐酸盐,Linsidomine) 目录号 : GC13152SIN-
Cas No.:16142-27-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
As the active metabolite of molsidomine, SIN-
SIN-1 (chloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the SIN-1 (chloride) inan organic solvent. SIN-1 (chloride) is soluble in organic solvents such as cthanol, DMSO, and dimethyl formamidc. Thesolubility of SIN-1 (chloride) in these solvents is approximately 5 mg/ml.
Further dilutions of the stock solution into aqucous buffers or isotonic saline should be made prior to performingbiological experimcnts. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may havcephysiological effects at low concentrations. Organic solvent-free aqucous solutions of SIN-1 (chloride) can be preparedby directly dissolving the crystalline compound in aqucous buffers. The solubility of SIN-1 (chloridc) in PBS (pH 7.2) isapproximately 10 mg/ml. We do not recommend storing the aqucous solution for more than one day.
As the active mctabolite of molsidominc, SIN-1 (chloride) is a potent vasorelaxant and inhibitor of platelet aggrcgationIt produces both NO and superoxide and can therefore be used to gencrate peroxynitrite under physiological conditions.1-3
WARNING This product is not for human or veterinary use.
References:
1.Rosenkranz, B, Winkelmann, B.R., and Parnham, M.J. Clinical pharmacokinctics of molsidomine. Clin. Pharmokinet.30,372-384(1996).
2.Lomonosova, E.E, Kirsch, M, Rauen, U, et al. The critical role of hepes in SIN-1 cytotoxicity, peroxynitrite versus2.hydrogen peroxidc. Free Radic. Biol Med. 24, 522-528 (1998).
3.Nishikawa, M., Kanamori, M., and Hidaka, H. Inhibition of platelet aggregation and stimulation of guanylate cyclascby an antianginal agent molsidomine and its metabolites. J. Pharmacol. Exp. Ther. 220, 183-190 (1982).
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.8396 mL | 24.1978 mL | 48.3957 mL |
5 mM | 0.9679 mL | 4.8396 mL | 9.6791 mL |
10 mM | 0.484 mL | 2.4198 mL | 4.8396 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。